Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies - Test2 - elhamkhani - TriplyDB

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

http://www.wikidata.org/entity/Q35669226

about

Regulation of Bim in Health and Disease Principles of allosteric interactions in cell signaling mTOR kinase inhibitors as potential cancer therapeutic drugs Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells Tailoring mTOR-based therapy: molecular evidence and clinical challenges.Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer.Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro.Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells.Molecular pathogenesis of mantle cell lymphoma.OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models.SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth.4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.CXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and Bak Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.Increased mammalian target of rapamycin complex 2 signaling promotes age-related decline in CD4 T cell signaling and function mTOR pathway in colorectal cancer: an update.An overview of the mTOR pathway as a target in cancer therapy.Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer.Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.Targeting mTOR for the treatment of B cell malignancies.Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research.Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.Waldenström Macroglobulinemia: Review of Pathogenesis and Management.mTOR Inhibitors at a Glance.Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.Catalytic mammalian target of rapamycin inhibitors as antineoplastic agents.

P2860

Q26781203-E6FB38E9-E4F3-4BC5-87B0-816ED2071C6A Q26996431-120AE81D-8CA8-4D8F-82F2-99EAF5830CC6 Q27027963-BF581672-3CD6-4280-9126-4F9CF6B8F20E Q27304386-64B0F41A-4A6E-4C12-9659-CE0B1992A80F Q28075606-CC03A678-4E27-418C-99C9-E52FF4ABC156 Q33574190-522C29E6-02E8-4514-A891-0C042DC26EA0 Q33586239-10E8FB37-F3C1-4F37-B5E4-57C2D54F4E37 Q33752594-AEE4DBDF-7005-4DF1-B7EC-76EADEAE3626 Q33808800-DDBEEEFC-A67C-47C2-AE02-DC128085B576 Q34294170-DFD0F9EA-6696-49C0-9E2E-EFC783C27066 Q35000084-B97F6CC6-0679-4F03-9997-BFA34799F1B3 Q35563024-0629BD95-52D6-4F4F-BABC-F35FB01914E2 Q35832407-B8A3F72B-E085-404F-A314-C50FCAE9235A Q35987363-8C3C8929-C3FE-4847-B2CF-30DC30AEBA6B Q36027204-3E5C1B83-F3BF-4794-A1F5-D9BB0220FD0F Q36199633-996CAA6F-4C99-40C9-A0D8-8EBDDC99F404 Q36290246-65CF5457-4FD7-4D56-AFEE-B373BC6FF622 Q36413415-6434FE48-0BCD-4E04-A66C-E54A45D9A471 Q36446451-CCDFAB60-2C11-447B-B6F9-7DDC3D84EF69 Q36688940-EE2BA896-E6C3-41F8-93D7-44378A78D673 Q36751575-05BCE8A5-A637-4874-8E47-6E34238243C6 Q36899877-D2D40302-05A6-4712-A517-4BBE44507818 Q36916277-92DE7D74-0DBF-4561-8A5D-41132280C01D Q36965860-148787C8-76CA-44B2-B4F5-4615728E5D6C Q37095358-E938E26C-8B53-47A8-AA2D-F203CC4B490C Q37120620-41993B39-61BE-409E-A9F4-8A294CBA97D1 Q37307472-29776BE8-EA85-4393-B59F-3BB8408EEEED Q37649634-C1C5E42D-30F0-4FB8-9CA2-6AA282E0B242 Q38001798-65C26199-23CC-4B57-A5EB-1FCBA10780BC Q38094782-FB216CF1-8C65-4B80-8914-C5AE17BDEC71 Q38212951-C46A933E-E9D0-411B-BB33-0767BC96D7A9 Q38218128-DB6B70CA-4CBA-475A-BE66-7678D8F14936 Q38709825-0E8A9BC1-6094-492D-BA33-3E9AB8C280C6 Q38991388-65786C84-FC66-4B37-B44E-CFD8206922FF Q39145770-795A26F4-B5D6-4146-8E2B-EAD45C1D6F07 Q39214071-5A8A0E50-D905-482F-933F-C872C5D483B5 Q40760533-1BFF0530-8560-478A-A174-0DA4C02F41D8 Q44679554-4C3A31B9-BF09-4765-9C98-E9AAEBC558DC Q48011957-835C1025-28DA-442B-B627-972C331908C3 Q48101340-65EBCDD9-F8D2-47E0-A64D-897D2139CF99

P2860

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

http://www.wikidata.org/entity/Q35669226

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Dual mTORC1/mTORC2 inhibition ...... tosis in lymphoid malignancies

@ast

Dual mTORC1/mTORC2 inhibition ...... tosis in lymphoid malignancies

@en

type

label

Dual mTORC1/mTORC2 inhibition ...... tosis in lymphoid malignancies

@ast

Dual mTORC1/mTORC2 inhibition ...... tosis in lymphoid malignancies

@en

prefLabel

Dual mTORC1/mTORC2 inhibition ...... tosis in lymphoid malignancies

@ast

Dual mTORC1/mTORC2 inhibition ...... tosis in lymphoid malignancies

@en

P1433

Q35669226-ACE5467F-B3D4-4C92-A52E-A9542F4EC42A

P1476

Q35669226-CFC83AEE-8C1A-4B6B-B0C5-E007E3E543F6

P2093

Q35669226-1B3B9C65-3450-47AF-BE82-94E3521D3D0C

Q35669226-41AC2C3A-5D78-44A5-BEBA-B558A05F6C92

Q35669226-4863D854-4C3F-41F6-A3E6-191266076D9D

Q35669226-48C71F6D-EFE3-4370-9F98-C40987DC7359

Q35669226-52D2BE04-EC73-4E5A-BA68-9D7C2199B6F5

Q35669226-7694A876-8A90-4E77-A825-F8019CBD0E0A

Q35669226-77EDC777-8A82-44C5-8CD0-C884970E9171

Q35669226-9C708EED-090E-4126-B581-F94EC11CDD90

Q35669226-A8000558-E9B8-4435-ABE4-A074697B5C7D

Q35669226-A94F2E29-1452-4CF4-85C9-D79F48B207B8

P2860

Q35669226-02479724-C406-4DA6-81D6-779A29BD69C8

Q35669226-054518EE-15E0-45A2-826A-1299384256F2

Q35669226-119E3D5C-5B17-4097-B8DD-7B176900B37A

Q35669226-18F3F854-BD48-4C6D-A6C3-2C6B9F81FB78

Q35669226-193FE596-32D1-405A-99F1-DC4F7C42D922

Q35669226-1D0F37E7-2D2F-420C-9C9A-6714249B292D

Q35669226-21685C6D-C800-48D9-987A-ED4990CC17C7

Q35669226-21C4F468-6A7F-449F-A153-607DB9C1643C

Q35669226-261E9AAD-AFC1-40E1-8CF3-3E950D216564

Q35669226-27B85F8C-F9F2-4D06-A43F-707BC8DAC2CD

P304

Q35669226-A3746312-EB3F-4A78-8CB8-E697F31C4110

P31

Q35669226-6F8913AD-F512-45E6-B45C-D33C6AD293AA

P356

Q35669226-CA35FB81-A668-427B-A1E1-B30F514F3C77

P407

Q35669226-E912C304-0D61-43A1-B612-DD14C7CB1EE0

P433

Q35669226-21B89F91-E50B-4FED-B666-29F96915402C

P478

Q35669226-B53697D8-FE4D-40D5-B788-F85A994F6DF1

P50

Q35669226-DC18AF11-F2A4-408F-8334-9B3A9D597003

P577

Q35669226-75663726-7E40-46FF-A77C-CDF8025FA58C

P5875

Q35669226-894EA8E0-1130-4009-80CC-69A44ABEC924

P698

Q35669226-DEEE86CC-AFAD-4F05-87FE-1BF332026C41

P932

Q35669226-541EF437-A3E3-4A38-B8C3-75A19D7E13BA

P356

BLOOD-2011-04-346601

P1433

P1476

Dual mTORC1/mTORC2 inhibition ...... tosis in lymphoid malignancies

@en

P2093

Allan D Hess

http://www.w3.org/2001/XMLSchema#string

Andrea E Wahner Hendrickson

http://www.w3.org/2001/XMLSchema#string

B Douglas Smith

http://www.w3.org/2001/XMLSchema#string

Brian D Koh

http://www.w3.org/2001/XMLSchema#string

Jennifer C Shing

http://www.w3.org/2001/XMLSchema#string

Jing Jing Han

http://www.w3.org/2001/XMLSchema#string

Judith E Karp

http://www.w3.org/2001/XMLSchema#string

Karen S Flatten

http://www.w3.org/2001/XMLSchema#string

Kevin L Peterson

http://www.w3.org/2001/XMLSchema#string

Linda E Wellik

http://www.w3.org/2001/XMLSchema#string

P2860

Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells

PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms

Cancer statistics, 2010

Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells

Defining the role of mTOR in cancer

PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth

mTOR and cancer therapy

Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma

The BCL-2 protein family: opposing activities that mediate cell death

Cellular survival: a play in three Akts

P304

476-487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-04-346601

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Scott H Kaufmann

P577

2011-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51796006

http://www.w3.org/2001/XMLSchema#string

P698

22080480

http://www.w3.org/2001/XMLSchema#string

P932

3257013

http://www.w3.org/2001/XMLSchema#string